Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000341039 | SCV000335683 | uncertain significance | not provided | 2015-10-02 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002487207 | SCV002785795 | uncertain significance | Rubinstein-Taybi syndrome due to CREBBP mutations; Menke-Hennekam syndrome 1 | 2021-09-20 | criteria provided, single submitter | clinical testing | |
Invitae | RCV002521902 | SCV003470103 | benign | Rubinstein-Taybi syndrome | 2022-06-13 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV003939977 | SCV004749955 | likely benign | CREBBP-related disorder | 2023-11-06 | criteria provided, single submitter | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |
Ce |
RCV000341039 | SCV004811637 | likely benign | not provided | 2024-03-01 | criteria provided, single submitter | clinical testing | CREBBP: BP4, BP7 |